New study looks at Selexipag's Long-Term effects on rare lung condition

This study looks at how well the oral medication selexipag works over the long term for people with a specific type of lung disease called schistosomiasis-associated pulmonary arterial hypertension. Researchers will compare patients who took selexipag with similar patients who did not, using data from routine medical care. The goal is to see if selexipag helps delay worsening of the disease and improves outcomes. About 30 adults will be included.